Wuhan Chegu Sci-tech Innovation Investment Fund, newly established in Wuhan Economic & Technological Development Zone (WEDZ), has completed its first round of funding, allocating resources to four cutting-edge technology companies in sensors, biopharma, and semiconductors.
The investments include Phoosgene Future Technology (Wuhan) Co, developer of China's first industrialized radon gas sensor; Zhongmou Therapeutics Co, creator of an FDA-designated orphan drug for retinal diseases; Wuhan Zhuojin Semiconductor Co, producer of advanced domestic wafer dicing machines; and Wuhan Shengshi Qichuang Technology Co, developer of breakthrough eddy current sensors for automotive applications.
The zone's first early-stage special fund has identified 68 potential projects since its launch in May. These initial investments align with Wuhan's "135" modern industrial system strategy, a strategic blueprint for industrial transformation focusing on hydrogen energy, advanced materials, integrated circuits, the low-altitude economy, and healthcare biotechnology, targeting technologies that strengthen local supply chains. The fund plans to utilize government capital to attract additional private investment, accelerating innovation in this key automotive manufacturing hub.
